Neuphoria Therapeutics, Inc.

Contributing Author

Recent Articles by Neuphoria Therapeutics, Inc.

Dec-08	Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees NEUP +6.32% GlobeNewswire
Dec-04	Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium NEUP GlobeNewswire
Dec-01	Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions NEUP GlobeNewswire
Nov-24	Neuphoria Therapeutics Inc. Sends Letter to Stockholders NEUP GlobeNewswire
Nov-11	Neuphoria Announces Initiation of Strategic Review to Maximize Stockholder Value NEUP GlobeNewswire
Oct-27	Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process NEUP -27.40% GlobeNewswire
Oct-20	Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder NEUP -68.51% NEUP GlobeNewswire
Sep-29	Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates NEUP GlobeNewswire
Sep-04	Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) NEUP -8.31% GlobeNewswire
Aug-28	Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference NEUP +19.47% NEUP -7.21% GlobeNewswire
May-27	Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting NEUP GlobeNewswire
May-20	Neuphoria Provides First Quarter 2025 Business Updates NEUP +9.86% GlobeNewswire